The PRESIDE (PhaRmacogEnomicS In DEpression) Trial: a double-blind randomised controlled trial of pharmacogenomic-informed prescribing of antidepressants on depression outcomes in patients with major depressive disorder in primary care

Abstract Background The evidence for the clinical utility of pharmacogenomic (PGx) testing is growing, and guidelines exist for the use of PGx testing to inform prescribing of 13 antidepressants. Although previous randomised controlled trials of PGx testing for antidepressant prescribing have shown...

وصف كامل

التفاصيل البيبلوغرافية
الحاوية / القاعدة:Trials
المؤلفون الرئيسيون: Sibel Saya, Patty Chondros, Anastasia Abela, Cathrine Mihalopolous, Mary Lou Chatterton, Jane Gunn, Timothy F. Chen, Thomas M. Polasek, Elise Dettmann, Rachel Brooks, Michelle King, Luke Spencer, Pavithran Alphonse, Shakira Milton, Georgia Ramsay, Zoe Siviour, Jamie Liew, Philip Ly, Matthew Thoenig, Raushaan Seychell, Floriana La Rocca, Luke B. Hesson, Nydia Mejias, Terri Sivertsen, Melanie Anne Galea, Chad Bousman, Jon Emery
التنسيق: مقال
اللغة:الإنجليزية
منشور في: BMC 2023-05-01
الموضوعات:
Major depressive disorder
Mental health
Pharmacogenomics
Primary care
General practice
Antidepressants
الوصول للمادة أونلاين:https://doi.org/10.1186/s13063-023-07361-6

مواد مشابهة

مواد مشابهة